Eastern Food Allergy & Comorbidity Conference 2023

January 5, 2023 to January 8, 2023

The 2023 EFACC activity will provide conference attendees with knowledge regarding novel food allergy developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology, particularly as it relates to food allergy and associated allergic comorbidities. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core learning objectives relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients food allergy and comorbid allergic diseases. Topics of discussion will include food allergy prevention, food allergy immunotherapy, asthma, atopic dermatitis, eosinophilic esophagitis and shared decision making.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Physicians and allied health staff providing care for food allergies.

Learning Objectives

At the conclusion of the activity learners should be ablet to:

  1. Initiate an appropriate evaluation and treatment strategy for eosinophilic esophagitis based on history, endoscopy, biopsy, and shared decision making.
  2. Discuss the risks and benefits of oral peanut challenges and peanut desensitization via immunotherapy.
  3. Discuss quality of life and psychological issues associated with food allergy.
  4. Explain the role of nutrition in the management of food allergy.
  5. Diagnose and treat comorbidities of food allergy including atopic dermatitis and asthma.
  6. Incorporate shared decision making into food allergy management.
  7. Appropriately treat anaphylaxis attributable to food allergy.
  8. Provide evidence-based advice regarding food allergy prevention to parents of infants at high risk for developing food allergy.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
Course opens: 
Course expires: 
Event starts: 
01/05/2023 - 2:00pm CST
Event ends: 
01/08/2023 - 12:00pm CST

Available Credit

  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
Please login or create an account to take this course.